HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease

Abstract

Chronic carriers of hepatitis B virus (HBV) who have to be immunosuppressed are at risk for HBV reactivation and hepatitis. Continuing immunosuppression in such patients and in immunosuppressed patients with active hepatitis B is strongly discouraged yet frequently inevitable. We here report on both the successful control of hepatitis and seroconversion after HBV reactivation following allogeneic hematopoietic stem cell transplantation (HSCT) with entecavir despite systemic immunosuppression.